Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | geminin | 0.0205 | 0.2984 | 0.2984 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0556 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0556 | 1 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0556 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0556 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.2984 | 0.2984 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0556 | 1 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0556 | 1 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0556 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0556 | 1 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0556 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0556 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0556 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 1 | 0.5 |
Echinococcus granulosus | geminin | 0.0205 | 0.2984 | 0.2984 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0556 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.2984 | 0.2984 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0556 | 1 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0556 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 1 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0556 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0556 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.092 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.9953 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 63.0957 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.